A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years

NCT02212106 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

402

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza, Human

Interventions

BIOLOGICAL: bioCSL Trivalent Influenza Virus Vaccine (CSL TIV)
BIOLOGICAL: Comparator Quadrivalent Influenza Virus Vaccine

Sponsor

Seqirus